Given that the immunomodulatory effects of MSCs have been shown to be most effective on CD4+ T cells, it is not surprising that MSCs have been utilized in the highest number of clinical trials aimed at treating autoimmune diseases. This evidence concerns the gene CD4 and autoimmune disease.